Although some reports raised the concern that anti-PD1 therapy may promote tumor proliferation in T-cell lymphoma,1,7,8 other studies demonstrated that anti-PD1 had efficacy in these neoplasms.9–11 Interestingly, the combination of Nivolumab with GemOx lead to high response rates and prolonged remissions (compared to first-line treatment) in a subset of patients. The gene discussed is PDCD1; the disease is T-cell non-Hodgkin lymphoma.